by European Public Health Alliance | Feb 10, 2023 | Position & Policy Papers
The transferable exclusivity voucher is a costly, complex and untested incentive for new antibiotics. It does not address access to new and old antibiotics, and it does not help with stewardship. We are worried that the European Commission plans to include the voucher...
by European Public Health Alliance | Jan 25, 2023 | Statements
To the EMA Executive DirectorTo the members of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)Cc: European Commission Brussels, 24 January 2023 Dear Chair and members of the MSSG, We are writing to you because we believe that the...
by European Public Health Alliance | Dec 15, 2022 | Reports
While the COVID-19 pandemic has brought access and affordability of medicines to the spotlight, it has also underscored the need for more balance, transparency, and accountability in the pharmaceutical sector. The 2022 Access to Medicines Forum coincides with the...
by European Public Health Alliance | Dec 1, 2022 | Opinion, Reports
More than 32 million adults and 170,000 children live with a form of diabetes in the EU. Although 14 types of diabetes have been identified so far, the most common are Type 1 and Type 2. Most cases of Type 2 Diabetes are preventable. Yet, Type 1 and other forms are...
by Cécile Bergmans | Nov 9, 2022
5th EPHA Universal Access and Affordable Medicines Forum 5 December 2022 09:00 - 17:00 Scotland House Brussels The access to medicines (A2M) Forum is a yearly event organised by EPHA to foster a meaningful and inclusive dialogue on access to medicines and...
